CN110396133B - 一种以白介素12为活性成分的融合蛋白型药物前体 - Google Patents

一种以白介素12为活性成分的融合蛋白型药物前体 Download PDF

Info

Publication number
CN110396133B
CN110396133B CN201810376920.1A CN201810376920A CN110396133B CN 110396133 B CN110396133 B CN 110396133B CN 201810376920 A CN201810376920 A CN 201810376920A CN 110396133 B CN110396133 B CN 110396133B
Authority
CN
China
Prior art keywords
ser
leu
val
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810376920.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110396133A (zh
Inventor
傅阳心
彭华
薛娣媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Kangkang Biotechnology Co.,Ltd.
Original Assignee
Immune Targeting Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201810376920.1A priority Critical patent/CN110396133B/zh
Application filed by Immune Targeting Inc filed Critical Immune Targeting Inc
Priority to CN201980042842.4A priority patent/CN112638938A/zh
Priority to BR112020021791-3A priority patent/BR112020021791A2/pt
Priority to CA3097995A priority patent/CA3097995A1/en
Priority to KR1020207033158A priority patent/KR20210024446A/ko
Priority to EA202092459A priority patent/EA202092459A1/ru
Priority to US17/049,021 priority patent/US12473337B2/en
Priority to JP2020559408A priority patent/JP2021521822A/ja
Priority to PCT/US2019/028933 priority patent/WO2019209965A2/en
Priority to AU2019261411A priority patent/AU2019261411B2/en
Priority to EP19792585.2A priority patent/EP3810639A4/en
Publication of CN110396133A publication Critical patent/CN110396133A/zh
Application granted granted Critical
Publication of CN110396133B publication Critical patent/CN110396133B/zh
Priority to JP2024197045A priority patent/JP2025032113A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810376920.1A 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体 Active CN110396133B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
CA3097995A CA3097995A1 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
KR1020207033158A KR20210024446A (ko) 2018-04-25 2019-04-24 인터루킨 12 융합 단백질 및 이의 조성물 및 치료 방법
EA202092459A EA202092459A1 (ru) 2018-04-25 2019-04-24 Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
US17/049,021 US12473337B2 (en) 2018-04-25 2019-04-24 Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
CN201980042842.4A CN112638938A (zh) 2018-04-25 2019-04-24 白介素12融合蛋白及其组合物和治疗方法
BR112020021791-3A BR112020021791A2 (pt) 2018-04-25 2019-04-24 proteínas de fusão de interleucina 12 e composições e métodos terapêuticos das mesmas
AU2019261411A AU2019261411B2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
EP19792585.2A EP3810639A4 (en) 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
JP2020559408A JP2021521822A (ja) 2018-04-25 2019-04-24 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法
JP2024197045A JP2025032113A (ja) 2018-04-25 2024-11-11 インターロイキン１２融合タンパク質および組成物、ならびにその治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体

Publications (2)

Publication Number Publication Date
CN110396133A CN110396133A (zh) 2019-11-01
CN110396133B true CN110396133B (zh) 2021-07-23

Family

ID=68294664

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810376920.1A Active CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
CN201980042842.4A Pending CN112638938A (zh) 2018-04-25 2019-04-24 白介素12融合蛋白及其组合物和治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980042842.4A Pending CN112638938A (zh) 2018-04-25 2019-04-24 白介素12融合蛋白及其组合物和治疗方法

Country Status (9)

Country Link
US (1) US12473337B2 (enExample)
JP (2) JP2021521822A (enExample)
KR (1) KR20210024446A (enExample)
CN (2) CN110396133B (enExample)
AU (1) AU2019261411B2 (enExample)
BR (1) BR112020021791A2 (enExample)
CA (1) CA3097995A1 (enExample)
EA (1) EA202092459A1 (enExample)
WO (1) WO2019209965A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200306301A1 (en) 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
WO2022129313A1 (en) * 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
WO2022204267A1 (en) * 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
IL312221A (en) 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4695282A1 (en) 2023-04-12 2026-02-18 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
CN105218682A (zh) * 2015-10-26 2016-01-06 深圳精准医疗科技有限公司 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置，半導体製造装置の流量補正方法，プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN105218682A (zh) * 2015-10-26 2016-01-06 深圳精准医疗科技有限公司 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
WO2017071173A1 (zh) * 2015-10-26 2017-05-04 杨世成 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN110396133A (zh) 2019-11-01
WO2019209965A3 (en) 2019-12-05
JP2021521822A (ja) 2021-08-30
KR20210024446A (ko) 2021-03-05
WO2019209965A2 (en) 2019-10-31
US20220162280A1 (en) 2022-05-26
EA202092459A1 (ru) 2021-06-15
CN112638938A (zh) 2021-04-09
JP2025032113A (ja) 2025-03-11
EP3810639A2 (en) 2021-04-28
AU2019261411B2 (en) 2024-11-14
CA3097995A1 (en) 2019-10-31
AU2019261411A1 (en) 2020-11-26
US12473337B2 (en) 2025-11-18
BR112020021791A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
CN110396133A (zh) 一种以白介素12为活性成分的融合蛋白型药物前体
JP7569820B2 (ja) Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
CN110437339B (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
JP6484634B2 (ja) Ｉｌ−１５ヘテロ二量体タンパク質及びその用途
Scheller et al. Interleukin-6 and its receptor: from bench to bedside
JP4787439B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
WO2019201161A1 (zh) 一种ifn与抗pd-l1抗体的融合蛋白及其应用
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
TW200539891A (en) Methods of modulating cytokine activity; related reagents
JPH08507201A (ja) リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
CA2583937A1 (en) Chimeric protein
JP2020508063A (ja) Ｃｓｆ１ｒベースのキメラタンパク質
WO2022089601A1 (zh) 一种il-2与抗体亚单位构成的双功能融合蛋白
US20250223329A1 (en) Bifunctional fusion protein composed of il-15 and antibody against t cell co-stimulatory molecule
EP4471068A1 (en) Bifunctional molecule formed by fusion of pd1 antibody and interleukin 2
US20080292628A1 (en) Chimeric Protein
CN108285493B (zh) 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
CN119638850A (zh) 双特异性细胞因子融合蛋白及其应用
CN103833856B (zh) 抑制taci‑baff复合物形成的融合蛋白及其制法和用途
WO2022089418A1 (zh) 重组截短FLT3配体与人抗体Fc的融合蛋白
WO2025129454A1 (zh) Il-15与t细胞共刺激分子抗体构成的双功能融合蛋白
CN117624379A (zh) 一种人工蛋白及其应用
JP3689111B2 (ja) インターロイキン１５
BR112020015030B1 (pt) Proteína de fusão compreendendo il-2 e cd80, dímero da dita proteína, usos dos mesmos para tratar câncer, bem como polinucleotídeo, vetor, microorganismo transformado e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210223

Address after: 4305 green Blair Avenue, Dallas, Texas, USA

Applicant after: Immune targeting Co.,Ltd.

Address before: 100101 Beijing city Chaoyang District Datun Road No. 15

Applicant before: Institute of Biophysics, Chinese Academy of Sciences

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240522

Address after: Room 8304, 3rd Floor, Building 10, No. 151 Libing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, March 2012

Patentee after: Shanghai Kangkang Biotechnology Co.,Ltd.

Country or region after: China

Address before: 4305 green Blair Avenue, Dallas, Texas, USA

Patentee before: Immune targeting Co.,Ltd.

Country or region before: U.S.A.